VALNEVA SE SP.ADS/2 (AYJ0) - Total Liabilities
Based on the latest financial reports, VALNEVA SE SP.ADS/2 (AYJ0) has total liabilities worth €292.67 Million EUR (≈ $342.16 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
VALNEVA SE SP.ADS/2 - Total Liabilities Trend (2021–2025)
This chart illustrates how VALNEVA SE SP.ADS/2's total liabilities have evolved over time, based on quarterly financial data. See VALNEVA SE SP.ADS/2 (AYJ0) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
VALNEVA SE SP.ADS/2 Competitors by Total Liabilities
The table below lists competitors of VALNEVA SE SP.ADS/2 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shyft Group Inc
NASDAQ:SHYF
|
USA | $333.76 Million |
|
Nanjing CEC Environmental Protect
SHE:300172
|
China | CN¥914.55 Million |
|
Shenzhen Kexin Communication Technologies Co Ltd
SHE:300565
|
China | CN¥848.80 Million |
|
SUNSEA Telecommunications Co Ltd
SHE:002313
|
China | CN¥2.99 Billion |
|
Huchems
KO:069260
|
Korea | ₩259.89 Billion |
|
Puradelta Lestari PT
JK:DMAS
|
Indonesia | Rp408.98 Billion |
|
Unifique Telecomunicações S.A.
SA:FIQE3
|
Brazil | R$1.49 Billion |
|
Zhanjiang Guolian Aquatic Products
SHE:300094
|
China | CN¥2.35 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down VALNEVA SE SP.ADS/2's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AYJ0 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VALNEVA SE SP.ADS/2's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VALNEVA SE SP.ADS/2 (2021–2025)
The table below shows the annual total liabilities of VALNEVA SE SP.ADS/2 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €292.67 Million ≈ $342.16 Million |
-8.19% |
| 2024-12-31 | €318.78 Million ≈ $372.69 Million |
-3.93% |
| 2023-12-31 | €331.81 Million ≈ $387.93 Million |
-17.37% |
| 2022-12-31 | €401.55 Million ≈ $469.45 Million |
-37.92% |
| 2021-12-31 | €646.77 Million ≈ $756.14 Million |
-- |
About VALNEVA SE SP.ADS/2
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more